Novel Therapeutic Agents for Acute Myeloid and Chronic Lymphocytic Leukemia

Novel Therapeutic Agents for Acute Myeloid and Chronic Lymphocytic Leukemia

Episodes

Specialty:

All

Year:

All

EP. 1: Treatment Options for Chronic Lymphocytic Leukemia

January 8th 2019

EP. 2: Mutational Drivers of Acute Myeloid Leukemia

January 8th 2019

EP. 3: Efficacy and Safety of Ibrutinib-Containing Regimens in CLL

January 8th 2019

EP. 4: Midostaurin Plus Chemotherapy for FLT3-Mutated AML Cases

January 8th 2019

EP. 5: Venetoclax for CLL After Progression on 1 Prior Therapy

January 8th 2019

EP. 6: Glasdegib, Gilteritinib, and Quizartinib Against AML

January 8th 2019

EP. 7: Venetoclax-Based Regimens as First-Line Therapy in CLL

January 8th 2019

EP. 8: Venetoclax-Based Regimens as First-Line Therapy in AML

January 8th 2019

EP. 9: Treatment Options for Relapsed/Refractory CLL

January 8th 2019

EP. 10: Treatment Options for Relapsed/Refractory AML

January 8th 2019

EP. 11: BTK/BCL2 Inhibitors & Other Novel Agents in CLL Therapy

January 8th 2019

EP. 12: IDH Inhibitors in AML Therapy

January 8th 2019

EP. 13: The Future of AML Therapy: Cause for Optimism

January 8th 2019

Trending on OncLive

ASCO Issues First Guideline on ctDNA Testing in Solid Tumors and Lymphoma

Intismeran Autogene Plus Pembrolizumab Meets RFS and DMFS End Points in Resected Stage IIB-IV Melanoma

The OncFive: Top Oncology Articles for the Week of 8/16

ESMO Guidelines Express Update Recommends Daraxonrasib for RAS G12–Mutated Metastatic PDAC

Darlifarnib Plus Cabozantinib Displays Early Signals of Safety and Efficacy in RCC